Subtle Alterations in Brain Anatomy May Change an Individual’s Personality in Chronic Pain

Sylvia M. Gustin1*, Jamie G. McKay2, Esben T. Petersen3, Chris C. Peck4, Greg M. Murray4, Luke A. Henderson2

1 Neuroscience Research Australia, Randwick, NSW, Australia, 2 Department of Anatomy and Histology, University of Sydney, Sydney, NSW, Australia, 3 Departments of Radiology and Radiotherapy, University Medical Center Utrecht, Utrecht, The Netherlands, 4 Faculty of Dentistry, University of Sydney, Sydney, NSW, Australia

Abstract

It is well established that gross prefrontal cortex damage can affect an individual’s personality. It is also possible that subtle prefrontal cortex changes associated with conditions such as chronic pain, and not detectable until recent advances in human brain imaging, may also result in subtle changes in an individual’s personality. In an animal model of chronic neuropathic pain, subtle prefrontal cortex changes including altered basal dendritic length, resulted in altered decision making ability. Using multiple magnetic resonance imaging techniques, we found in humans, although gray matter volume and on-going activity were unaltered, chronic neuropathic pain was associated with reduced free and bound proton movement, indicators of subtle anatomical changes, in the medial prefrontal cortex, anterior cingulate cortex and mediodorsal thalamus. Furthermore, proton spectroscopy revealed an increase in neural integrity in the medial prefrontal cortex, anterior cingulate cortex and mediodorsal thalamus. It is also evident that chronic pain is associated with subtle anatomical alterations in the thalamus, insular and cingulate cortices [1,2,3]. It is also evident that chronic pain is associated with altered temperament changes such as reduced novelty seeking and increased harm avoidance that occur in human brain imaging, may also result in subtle changes in an individual’s personality. In an animal model of chronic pain, basal dendrites of pyramidal neurons within the mPFC were longer and had more branches than in sham-operated rodents. In addition, pain was associated with increased spine density and increased contribution of the NMDA component of synaptic currents. If similar changes in mPFC anatomy occur in humans, they may underlie at least in part the altered temperament changes such as reduced novelty seeking and increased harm avoidance that occur in human brain imaging, may also result in subtle changes in an individual’s personality.

Introduction

It is well established that gross prefrontal cortex damage can alter an individual’s personality. Less recognized is the possibility that in individuals with conditions such as chronic pain, subtle changes in prefrontal cortex anatomy associated with the condition, may also result in subtle changes in an individual’s personality. The lack of recognition of a connection between personality and brain anatomy, likely stems from the fact that until recently, it was almost impossible to assess subtle changes in brain anatomy in living humans. The recent use of more sensitive brain imaging techniques has revealed that chronic pain is associated with subtle anatomical alterations in the thalamus, insular and cingulate cortices [1,2,3]. It is also evident that chronic pain is associated with subtle, less well known, cognitive changes. For example, subjects with chronic pain display impaired emotional-based decision making [4,5], that is, they have decreased ability to think clearly and make advantageous decisions. In addition, it has recently been reported that chronic pain subjects display altered personality temperaments such as increased harm avoidance, i.e. excessive worrying, and low novelty seeking, i.e. reduced appetite for new experiences and reduced impulsive decision making [6].

It has been proposed that cognitive changes associated with chronic pain may result from alterations in activity within cortical areas such as the prefrontal cortex [7,8,9,10]. In a recent animal investigation, Metz and colleagues [11] found that in the spared nerve injury model of neuropathic pain, basal dendrites of pyramidal neurons within the mPFC were longer and had more branches than in sham-operated rodents. In addition, pain was associated with increased spine density and increased contribution of the NMDA component of synaptic currents. If similar changes in mPFC anatomy occur in humans, they may underlie at least in part the altered temperament changes such as reduced novelty seeking and increased harm avoidance that occur in human brain imaging, may also result in subtle changes in an individual’s personality. The study aims to explore anatomical and biochemical changes within the mPFC and related brain regions in individuals with chronic pain and to determine if any changes are associated with an individual’s personality. Diffusion tensor imaging (DTI) and T2-relaxometry was used to detect subtle changes that indicate alterations in the physical organization and myelination and/or development of axons and dendrites [12,13]. Additionally, spectroscopy can reveal biochemical changes, e.g. N-acetyl aspartate (NAA), an indicator of neuronal viability [14]. We hypothesize that in chronic pain subjects, the mPFC will display decreased DTI and T2 relaxation parameters and increased NAA levels and that these changes will be significantly related to an individual’s personality temperament of novelty seeking and harm avoidance. Such alterations would show that this region has undergone subtle changes in neuronal anatomy consistent with...
increased dendritic spine lengths, dendritic spine numbers and neuronal cell bodies.

Methods

Twenty two subjects with chronic pain (painful trigeminal neuropathy; 18 females, mean age 49.8±1.8 years [±SEM]) and 43 healthy controls without ongoing pain (35 females; mean age 46.4±2.7 years) were recruited at the University of Sydney, Australia. All chronic pain subjects were diagnosed with trigeminal neuropathy according to the Liverpool criteria [15]. After complete description of the study to the subjects, written informed consent was obtained for all procedures and the study was approved by Institutional Human Research Ethics Committees, University of Sydney. Some of the chronic pain subjects used in this study were also used in previous investigations [1,16,17,18,19].

Psychophysical Measures

Each chronic pain patient rated their on-going pain intensity with a vertical pencil stroke on a 10 cm horizontal line (visual analogue scale [VAS]; 0 cm = “no pain” to 10 cm = “maximum imaginable pain”) three times a day for the week prior to the scanning session. These pain values were averaged to provide an indication of each subject’s chronic pain rating. Each chronic pain subject also completed a McGill Pain Questionnaire and drew a distribution map of their on-going pain.

To assess individual subject’s temperament, 19 chronic pain (16 females; mean age [±SEM]: 53±1.8) and 30 control subjects (24 females; age: 51±1.0) completed the revised version of the temperament and character inventory (TCI-R) [20]. Significant differences between these temperament measures in chronic pain subjects and controls were determined using t tests (p<0.05).

Table 1. Characteristics of chronic pain subjects.

| Subject | Age  | Gender | Duration of pain (years) | Site   | Ongoing pain (10 cm VAS) | Analgesic Medication |
|---------|------|--------|--------------------------|--------|-------------------------|----------------------|
| 1       | 51   | M      | 3.5                      | right  | 2.1                     | Amitriptyline Hydrochloride |
| 2       | 48   | F      | 9.0                      | bilateral | 2.5                | Gabapentin          |
| 3       | 42   | F      | 2.0                      | right  | 5.5                     | Neurontin            |
| 4       | 64   | F      | 11.0                     | right  | 5.0                     | Gabapentin            |
| 5       | 52   | F      | 3.5                      | right  | 4.5                     | none                  |
| 6       | 47   | F      | 5.0                      | left   | 1.1                     | none                  |
| 7       | 53   | F      | 2.5                      | right  | 1.5                     | none                  |
| 8       | 52   | F      | 1.5                      | bilateral | 6.9                | Gabapentin            |
|         |      |        |                          |        |                         | Oxycodone            |
|         |      |        |                          |        |                         | Paracetamol         |
| 9       | 55   | F      | 2.0                      | left   | 5.2                     | Amitriptyline Hydrochloride |
|         |      |        |                          |        |                         | Gabapentin            |
|         |      |        |                          |        |                         | Oxycodone            |
|         |      |        |                          |        |                         | Paracetamol         |
|         |      |        |                          |        |                         | Ibuprofen (PRN)      |
|         |      |        |                          |        |                         | Carbamazepine        |
| 12      | 42   | F      | 11.0                     | bilateral | 4.8                | Paracetamol          |
|         |      |        |                          |        |                         | Gabapentin            |
|         |      |        |                          |        |                         | Pregabalin Nortriptyline |
| 13      | 48   | F      | 1.3                      | bilateral | 2.6                | Paracetamol          |
|         |      |        |                          |        |                         | Ibuuprofen           |
|         |      |        |                          |        |                         | Carbamazepine        |
| 14      | 34   | M      | 5.0                      | bilateral | 3.5                | Pregabalin Nortriptyline |
| 15      | 59   | F      | 5.0                      | left   | 3.3                     | Paracetamol          |
|         |      |        |                          |        |                         | Ibuuprofen           |
| 16      | 54   | F      | 2.0                      | right  | 1.6                     | Paracetamol          |
| 17      | 44   | F      | 6.5                      | bilateral | 6.4                | none                  |
| 18      | 40   | F      | 3.5                      | bilateral | 4.0                | Carbamazepine        |
| 19      | 67   | F      | 14.0                     | left   | 8.4                     | none                  |
| 20      | 43   | M      | 16.0                     | left   | 5.8                     | Amitriptyline        |
| 21      | 44   | F      | 7.0                      | bilateral | 1.2                | none                  |
| 22      | 65   | F      | 1.5                      | bilateral | 2.5                | none                  |

Mean (±SEM) 49.8 (±1.8) 5.7 (±0.9) 4.0 (±0.4)

PRN: Pro re nata – “as needed”.

doi:10.1371/journal.pone.0109664.t001
Table 2. T2 relaxation, mean diffusivity, grey matter volume and cerebral blood flow values within the contralateral medial prefrontal cortex (mPFC), anterior cingulate cortex (ACC), mediodorsal thalamus, ipsilateral posterior insula and contralateral primary somatosensory cortex (S1).

|                         | controls  | contralateral mPFC | contralateral ACC | contralateral mediodorsal thalamus | ipsilateral posterior insula | contralateral S1 |
|-------------------------|-----------|--------------------|------------------|-----------------------------------|-----------------------------|-----------------|
| T2 relaxation time (ms ± SEM) | chronic pain | 132 ± 4*            | 110 ± 3*          | 118 ± 7*                          | 124 ± 5*                   | 104 ± 4*        |
| Mean diffusivity (mm²/s × 10⁻³ ± SEM) | chronic pain | 1.16 ± 0.03*        | 1.02 ± 0.02*      | 1.36 ± 0.04*                      | 1.14 ± 0.04               | 1.02 ± 0.02*    |
| Grey matter volume (prob*vol ± SEM) | chronic pain | 0.46 ± 0.01        | 0.47 ± 0.01       | 0.49 ± 0.01                       | 0.64 ± 0.01               | 0.36 ± 0.01     |
| Cerebral blood flow (ml/min/g ± SEM) | chronic pain | 31.1 ± 1.8        | 34.5 ± 2.2        | 37.9 ± 3.1                        | 29.2 ± 2.3                | 38.6 ± 2.8      |

*significantly different to control subjects (p<0.05).
doi:10.1371/journal.pone.0109664.t002

MRI Acquisition
In all subjects, three 3D T1-weighted anatomical image sets (echo time = 2.5 ms, repetition time [TR] = 5600 ms, flip angle = 8°, voxel size = 0.8×0.8×0.8 mm) and four high-resolution diffusion tensor image sets (TR = 8788 ms; flip angle = 90°, voxel size = 2×2×2.5 mm, 32 directions, b = 0 and 1000 s/mm²) covering the entire brain were collected using a 3T Philips Intera machine. Three T1-weighted images and 4 DTI series were collected separately for subsequent averaging. In 39 of the 43 controls and 4 of the 22 chronic pain subjects, proton density and T2-weighted images covering the entire brain were also collected (TR = 4330 ms; echo times: 20, 40, 60, 80, 100 ms; voxel size = 2×2×2.5 mm). Multiple echo times were used to create multiple images for the subsequent calculation of T2-relaxation maps. In 24 controls and 18 chronic pain subjects, a quantitative arterial spin labelling (QASL) series, encompassing the entire brain was collected (TR/TE/DTI/T1 = 4000/23/300/40 ms, 64×64 matrix, 14 slices, FOV = 240×240, flip-angle = 35/11.7°, SENSE = 2.5, Venc = [8, 4 cm/s], 82 (48 @ Venc = 4 cm/s, 24 @ Venc = ∞, 10 low flip angle, all implemented in a two separate sequences) [21]. In addition, a series of T1-weighted anatomical images, at the same slice locations as the QASL images were collected.

All neuropathic pain and healthy subjects were asked to return for a second scanning session. Twelve control (11 females; mean age±SEM: 53.4±3.1) and 11 neuropathic pain subjects (10 females; mean age±SEM: 53.5±2.8) returned for the second scanning session, the remaining subjects declined to return. Proton magnetic resonance spectroscopy (1H-MRS) was performed on the contralateral (to pain) mPFC and on the right mPFC in control subjects (TR = 2000 ms; echo time = 29 ms, 1024 acquisition points, spectral width of 2 kHz, total acquisition time = 9 min, voxel size 20×15×30 mm). The location of the region selected was based on the diffusion and T2 relaxometry results. Automatic shimming (pencilbeam auto first order option) was performed resulting in line widths of <10 Hz for all spectra. There were no significant differences in age (p>0.05, t-test) or gender composition (p>0.05; Chi2 test) in any of the MRI analyses.

MRI Analysis

DTI. All images were processed using SPM8 [22] and custom software. The diffusion-weighted images were motion corrected, coregistered to one another, averaged and diffusion tensors calculated [12]. Mean diffusivity maps were derived, spatially normalized and smoothed (6mm full-width-at-half-maximum [FWHM] Gaussian filter). Significant differences in mean diffusivity between controls and chronic pain subjects were determined (p<0.05, random effects, family wise error corrected for multiple comparisons, minimum cluster 30 voxels, age and gender nuisance variables). Mean diffusivity values of significantly different clusters were extracted and significance verified (2 sample t-tests, p<0.05). Significant correlations between mean diffusivity and pain intensity, pain duration, and temperament values (novelty seeking etc) were determined (p<0.05). Significant differences in r-values in chronic pain compared with controls were also determined using Fisher r-to-z transformation (p<0.05).

T2 relaxometry. The following equation was used to calculate T2 brain maps: T2 = (TE2−TE1)/ln(SI1/SI2) where TE1 and TE2 are the echo times for proton density and T2-weighted images, and SI1, SI2 represent proton density and T2-weighted image signal intensities, respectively. A ceiling threshold of 500 ms was applied to eliminate cerebrospinal fluid. In each subject, one of the T2-weighted images (TE = 60 ms) was spatially normalized and the parameters applied to the T2 map. The spatially normalized T2 map was smoothed (6 mm FWHM) and significant differences in T2 relaxation times between controls and chronic pain subjects were determined (p<0.05, random effects, family wise error corrected for multiple comparisons, minimum cluster 30 voxels, age and gender nuisance variables). T2 relaxation times of significantly different clusters were extracted and significance verified (2 sample t-tests; p<0.05). Significant correlations between T2 relaxation times and pain intensity, pain duration, and temperament values (novelty seeking etc) were determined (p<0.05). Significant differences in r-values in chronic pain compared with controls were determined using Fisher r-to-z transformation (p<0.05).

Voxel based morphometry. T1-weighted anatomical image sets were coregistered to one another, averaged, modulated,
spatially normalized, segmented and smoothed (6 mm FWHM). Gray matter volumes from significant mean diffusivity and T2 relaxation clusters were extracted and compared between control and chronic pain subjects (2-tailed, 2-sample t-tests, p < 0.05).

Quantitative arterial spin labelling. QASL images were opened [21] and cerebral blood flow (CBF) maps created. In addition, anatomical (gray/white) image sets were created from the CBF maps. These anatomical images were then co-registered to the T1-weighted anatomical image set collected at the same slice locations and the resulting parameters applied to the CBF maps. The T1-weighted anatomical images were then normalized and the parameters applied to CBF maps. CBF values from significant mean diffusivity and T2 relaxation clusters were extracted and compared between control and chronic pain subjects (2-tailed, 2-sample t-tests, p < 0.05).

Proton magnetic resonance spectra (1H-MRS). MRS data were analyzed in the time domain using the Java-based magnetic resonance user’s interface (jMRUI 4.1, European Union project). The dominant water resonance was removed using the Hankel Lanczos Singular Valve Decomposition algorithm. All metabolite resonances were quantified using QUEST (containing a 29 ms TE metabolite basis set including N-acetylaspartate.

**Figure 1.** Brain regions in which T2-relaxation times (upper panel) or mean diffusivity values (lower panel) were significantly reduced in subjects with painful trigeminal neuropathy compared with pain-free, healthy controls. Significant reductions are colour-coded according to t-value and overlaid onto axial, coronal and sagittal sections of an individual subject’s T1-weighted image set. Slice locations in Montreal Neurological Institute space are indicated at the lower left of each image. ACC: anterior cingulate cortex; 1psi: ipsilateral to side of on-going pain; MD: mean diffusivity; mPFC: medial prefrontal cortex; S1: primary somatosensory cortex.

doi:10.1371/journal.pone.0109664.g001
(NAA), Creatine [23], Aspartate, Glutamate, Glutamine, Myo-Inositol (MI) and Glycerolphosphocholine. Ratios were calculated for NAA relative to Cr and MI relative to Cr. Significant differences in metabolite ratios between chronic pain subjects and healthy controls were determined (t-tests, \( p < 0.05 \)). One-tailed Pearson correlation test was used to determine significant (\( p < 0.05 \)) correlations between NAA/Cr ratios, MI/Cr ratios and pain intensity and pain duration.

**Results**

**Pain and Temperament**

Chronic pain subjects had on-going orofacial pain with mean pain intensity of 4.0 ± 0.4 and mean pain duration of 5.7 ± 0.9 years (Table 1). Chronic pain subjects had significantly lower mean novelty seeking values ([mean ± SEM] controls: 102 ± 2; chronic pain: 95 ± 2) and significantly higher harm avoidance values (control: 89 ± 3; chronic pain: 105 ± 4) compared with controls. In contrast, there were no significant differences in temperament scores of reward dependence (control: 106 ± 2; chronic pain), or persistence (control: 124 ± 4; chronic pain: 117 ± 5).

**T2 relaxation times and mean diffusivity**

Chronic pain subjects had reduced T2 relaxation times in the contralateral (to pain) subgenual anterior cingulate cortex (ACC), contralateral ACC and medial prefrontal cortices, ipsilateral posterior insula, contralateral medial thalamus and primary somatosensory cortex bilaterally (Figure 1, Table 2). Remarkably, whole brain analysis of mean diffusivity changes revealed significant decreases in these same regions apart from the subgenual ACC. Chronic pain subjects displayed significantly reduced mean diffusivity in the contralateral ACC, mPFC, ipsilateral posterior insula, contralateral medial thalamus (in the region of the mediodorsal nucleus) and primary somatosensory cortex bilaterally (Figure 1, Table 2). Brain regions where chronic pain subjects showed significant decreases in both T2 relaxation times and mean diffusivity are shown in Figure 2. Extraction of T2 relaxation times and mean diffusivity values from regions further confirmed these significant differences (Figure 3). Given the potential influence of medication we compared T2 relaxation times and mean diffusivity values within the mPFC, ACC and thalamus and found no significant differences between those chronic pain subjects taking medication (\( n = 8 \)) to those who were not (\( n = 14 \)). Furthermore, given the well-documented connections and functional interactions between the mediodorsal thalamus, mPFC and ACC [24], we restricted most of the remaining analysis on these three brain regions.

**Gray matter volumes and baseline blood flow**

Voxel based morphometry of T1-weighted anatomical images revealed that chronic pain was not associated with significant gray matter volume changes within the mPFC, ACC, mediodorsal thalamus, dorsal insula, or primary somatosensory cortex. Similarly, assessment of baseline regional cerebral blood flow using QASL revealed no significant difference in cerebral blood flow in chronic pain subjects compared with controls in the mPFC, ACC, mediodorsal thalamus, dorsal insula or primary somatosensory cortex (Figure 3, Table 2).

**Proton magnetic resonance spectra (1H-MRS)**

Finally, to assess biochemical changes within the mPFC, proton spectroscopy was performed. Within the contralateral mPFC, spectral analysis revealed that chronic pain subjects had significant elevated levels of N-acetyl aspartate/Creatine (NAA/Cr) compared to controls (mean ± SEM NAA/Cr: controls: 1.16 ± 0.03,
chronic pain: 1.32±0.04; p<0.005) (Figure 4). No significant difference in myo-inositol/Cr (MI/Cr) was found in the mPFC of chronic pain subjects compared to controls (mean±SEM MI/Cr; controls: 0.78±0.03, chronic pain: 0.72±0.02; p>0.05).

Relationships with pain and temperament
Within the mPFC, ACC and thalamus, T2 relaxation times and mean diffusivity values in chronic pain subjects were not significantly correlated with either on-going pain intensity or pain duration. In contrast, within the mPFC and ACC, T2 relaxation

Figure 4. Sagittal slice showing location from which proton spectroscopy was performed in the contralateral medial prefrontal cortex (mPFC) of subjects with chronic pain and pain-free controls. The bar graph shows mean (±SEM) NAA/Cr values for chronic pain patients and healthy controls. To the right are two plots of novelty seeking against mPFC NAA/Cr and mPFC T2 relaxation times against mPFC NAA/Cr. Note that both novelty seeking and mPFC T2 relaxation times are significantly correlated to NAA/Cr within the mPFC. NAA: N-acetyl aspartate; Cr: creatine.

doi:10.1371/journal.pone.0109664.g004
times were positively correlated to novelty seeking (mPFC: $r = 0.71$; ACC: $r = 0.77$) (Figure 5). That is, the greater the decrease in T2 relaxation times, the lower the individual’s novelty seeking score. In contrast, no significant relationship occurred between T2 relaxation times and novelty seeking within the thalamus ($r = 0.42$), or between T2 relaxation times and harm avoidance in all three regions (mPFC; $r = -0.12$; ACC: $r = -0.36$; mediodorsal thalamus: $r = -0.06$). In control subjects, no significant correlations were found between T2 relaxation times and either novelty seeking or harm avoidance in the mPFC, ACC or thalamus.

In chronic pain subjects NAA/Cr ratios within the mPFC were negatively correlated to novelty seeking ($r = -0.55$; Figure 5). That is, the greater the increase in NAA/Cr levels, the lower the individual’s novelty seeking score. Furthermore, there was a significant negative correlation between mPFC NAA/Cr and T2 relaxation times within the mPFC ($r = -0.54$). That is the greater the neural viability, the lower the T2 relaxation time. No significant relationship occurred between mPFC NAA/Cr levels and harm avoidance ($r = 0.02$). In control subjects, no significant relationship occurred between mPFC NAA/Cr and MI/Cr ratios and either novelty seeking (NAA/Cr: $r = 0.19$; MI/Cr: $r = -0.12$), or harm avoidance (NAA/Cr: $r = -0.18$; MI/Cr: $r = -0.04$).

Discussion

Our results reveal that chronic pain is associated with significant anatomical changes within brain regions known to underpin an individual’s personality traits, i.e. the mPFC, ACC and mediodorsal thalamus. Strikingly, in chronic pain subjects only, the anatomical and biochemical changes within the mPFC and ACC were significantly correlated to the personality temperament of novelty seeking, with greater anatomical change associated with reduced novelty seeking. These data suggest that subtle change in brain anatomy may alter an individual’s personality characteristic.

Metz and colleagues [11] investigated the mPFC in the spared nerve injury model of neuropathic pain and reported that basal dendrites of pyramidal neurons in the contralateral mPFC, were longer, had more branches and had greater spine densities than those in sham-operated animals. Similar anatomical changes in humans would result in decreased mean diffusivity, since increased dendritic length and spine density would result in more restricted movement of free protons, and decreased T2 relaxation times, since axon and dendrite development results in increases in binding potential for protons of free water molecules to the surrounding macromolecules [13,25,26]. This is precisely what we found in our chronic pain subjects. Additionally, one would predict that such subtle changes in neuronal morphology would not result in a gross change in gray matter volume. Consistent with this we found that gray matter volume within the mPFC, as well as the ACC, and mediodorsal thalamus, did not display a significant change in chronic pain subjects compared with healthy pain-free controls.

Although taken alone, the mean diffusivity and T2 relaxation changes in our chronic pain subjects may reflect alterations in glia or blood vessels, our spectroscopy data reveals that these changes are also associated with increased NAA and no change in myoinositol. NAA occurs almost exclusively in neurons and is widely accepted as a marker of neuronal viability and synaptic health [27,28]. Increased NAA levels are associated with better cognitive test performance and reduced levels occur in neurodegenerative diseases [29,30]. In contrast, myoinositol is thought to be a glial marker, with elevated levels interpreted as gliosis in conditions such as Alzheimer’s disease [31,32]. Although subject numbers of the spectroscopy scanning session were limited, we are confident that the changes in mean diffusivity and T2 relaxation reflect subtle neuronal changes such as altered basal dendritic length and spine density because we found increased levels of NAA and no change in myoinositol within the mPFC.

It is becoming increasingly clear that chronic pain is characterized not only by an ongoing sensory and emotional experience, but also significant changes in an individual’s cognitive ability. For example, it has been reported that chronic pain subjects display impaired decision making in the Iowa Gambling Task, making disadvantageous choices that gained high immediate monetary returns at the risk of higher future losses, i.e., they were less sensitive to future consequences [4,5]. Indeed, gross lesions of the mPFC and/or amygdala also result in decreased sensitivity to future consequences and poor performance on the Iowa Gambling Task [7,8,33]. Our chronic pain subjects had reduced novelty seeking and increased harm avoidance temperaments, a result consistent with a recent investigation, in which the personality profiles of over 200 chronic pain subjects were explored [6]. Furthermore, we found that novelty seeking, but not harm avoidance was significantly correlated to T2 relaxation times within the mPFC and ACC and NAA levels within the mPFC. Cloninger described novelty seeking as a “tendency toward intense exhilaration or excitement in response to novel stimuli ... which

Figure 5. Plots of T2 relaxation times against novelty seeking temperament in control subjects (black circles) and in chronic pain subjects (gray squares) within the medial prefrontal cortex, anterior cingulate cortex and mediodorsal thalamus.
leads to frequent exploratory activity in pursuit of potential rewards as well as active avoidance of monotony and potential punishment” [34]. The reduced novelty seeking in our chronic pain subjects implies that they are less likely to actively avoid monotony and potential punishment, which is consistent with being less sensitive to future consequences. Novelty seeking temperaments are thought to reflect the brain’s “behavioural activation” system [33] which depends on the integrity of the mesolimbic dopaminergic pathway, of which the mPFC and ACC are integral parts [36,37]. In a number of psychiatric conditions, loss or impairment of PFC function is associated with cognitive deficits and conditions characterized by reduced dopaminergic activity such as Parkinson’s disease, are associated with reduced novelty seeking temperaments [38,39].

The mPFC and ACC receive dopaminergic inputs directly from neurons within the ventral tegmental area. In experimental animals, ventral tegmental area lesions also result in cognitive deficits such as decreased exploration of environmental stimuli and reduced investigative behaviour [40]. Furthermore, dopamine depletion of the mPFC by 6-hydroxydopamine ventral tegmental area lesions, results in decreased basal dendritic lengths and spine densities of mPFC pyramidal cells [41]. Although in the opposite direction, these morphological changes are remarkably comparable in nature to those reported in the mPFC of experimental animals with neuropathic pain and supported by our MRI findings in humans with neuropathic pain. Importantly, given the unilateral nature of the mPFC anatomical changes that occur in the animal model of neuropathic pain (contralateral to injured nerve) and the unilateral nature of our MRI findings (contralateral to pain), it appears that the mPFC, ACC and thalamic anatomical changes associated with pain may result from the condition itself and may not pre-exist the injury/pain. It is possible that following neural injury, altered dopaminergic inputs result in increased basal dendrite lengths and increased spine densities of mPFC neurons, which in combination with inputs from other brain regions (e.g. amygdala), result in altered cognitive functions/temperaments such as novelty seeking and decision making ability. Interestingly, evidence is arising that chronic pain patients also have low Self-Directedness [6,42]. Indeed, a low value in self-directedness can predict the presence of a personality disorder [20]. Future research should examine the interaction of Novelty Seeking and Self-Directedness on brain biochemistry, structure and function, particularly within the mPFC.

Our data reveal that subtle neural changes in the mPFC and ACC of individuals with chronic pain are associated with subtle differences in an individual’s personality profile. Of course it is well established that gross anatomical alterations in the prefrontal and cingulate cortices can drastically alter an individual’s personality; the case of Phineas Gage is a prime example. Although our data cannot implicate causality, it may provide an indication that even subtle brain alterations can change an individual’s personality. Interestingly, in healthy individuals the temperament Persistence has been shown to be associated with an overlapping circuit including the ACC, ventral striatum and the lateral orbital and mPFC [43,44]. As this association is lacking in pain patients, this may show that the reduction in Novelty Seeking involving reduced active avoidance may be an adaptive process generated by subtle brain alterations after the development of neuropathic pain. Since the recent advent of more sensitive structural magnetic resonance imaging techniques, it is now known that many relatively common medical conditions are associated with significant changes in brain anatomy, including changes within the mPFC and ACC. For example, gray matter volumes in the mPFC and ACC are significantly altered in subjects with respiratory disorders [45], diabetes [46], osteoarthritis [47] and even obesity [40]. Given this, it is likely that most individuals will experience at least some subtle change in brain anatomy over their life time that may potentially result in a change in their personality profile. The idea that an individual’s personality is carried effectively unaltered throughout their adult life might need reconsideration.

Author Contributions
Conceived and designed the experiments: SG GM CP LH. Performed the experiments: SG GM CP LH. Analyzed the data: SG JM GM CP LH EP. Contributed reagents/materials/analysis tools: EP. Contributed to the writing of the manuscript: SG GM CP LH.

References
1. Gustin SM, Peck CC, Wilcox SL, Nash PG, Murray GM, et al. (2011) Different pain, different brain: thalamic anatomy in neuropathic and non-neuropathic chronic pain syndromes. J Neurosci 31: 5956–5964.
2. Burguer M, Gaubitz M, Konrad C, Wrenner M, Hilgert S, et al. (2009) Decreased gray matter volumes in the cingular-frental cortex and the amygdala in patients with fibromyalgia. Psychiatom Med 71: 566–573.
3. Younger JW, Shen YF, Goddard G, Mackey SC (2010) Chronic myofascial temporomandibular pain is associated with neural abnormalities in the trigeminal and limbic systems. Pain 149: 222–229.
4. Aparajitesh AV, Sosa Y, Krauss BR, Thomas PS, Fredrickson BE, et al. (2004) Chronic pain patients are impaired on an emotional decision-making task. Pain 108: 129–136.
5. Verdejo-Garcia A, Lopez-Torreillas F, Calandre EP, Delgado-Rodriguez A, Bechara A (2009) Executive function and decision-making in women with fibromyalgia. Arch Clin Neuropsych 24: 113–122.
6. Conrad R, Schilling G, Bausch C, Nadstawek J, Wartenberg HC, et al. (2007) Temperament and character personality profiles and personality disorders in chronic pain patients. Pain 133: 197–209.
7. Bechara A, Damasio H, Damasio AR, Lee GP (1999) Different contributions of the human amygdala and ventromedial prefrontal cortex to decision-making. J Neurosci 19: 5473–5481.
8. Bechara A, Dolan S, Drevberg N, Hines A, Anderson SW, et al. (2001) Decision-making deficits, linked to a dysfunctional ventromedial prefrontal cortex, revealed in alcohol and stimulant abusers. Neuropsychologia 39: 376–389.
9. Damasio H, Grabowski T, Frank R, Galaburda AM, Damasio AR (1994) The return of Phineas Gage: clues about the brain from the skull of a famous patient. Science 264: 1102–1105.
10. Schwartz MD, Diaz A, Martini ET, Rufino A, Amante LN, et al. (2008) Psychiatric disorders and traumatic brain injury. Neuropsychiatr Dis Treat 4: 797–816.
11. Metz AE, Yau HJ, Centeno MV, Aparajitesh AV, Martina M (2009) Morphological and functional reorganization of rat medial prefrontal cortex in neuropathic pain. Proc Natl Acad Sci U S A 106: 2423–2428.
12. Basar E, Pierpaoli C (1996) Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J Magn Reson B 111: 209–219.
13. Mathur-De Vree R (1984) Biodemical implications of the relaxation behaviour of water related to NMR imaging. Br J Radiol 57: 955–976.
14. Barber PB (2001) N-acetyl aspartate–a neuronal marker? Ann Neurol 49: 423–424.
15. Nurminho T, Eldridge PR (2001) Trigeminal neuralgia–pathobiology, diagnosis and current treatment. Br J Anesth 87: 117–132.
16. Gustin SM, Peck CC, Cheney LB, Macey PM, Murray GM, et al. (2012) Pain and Plasticity: Is Chronic Pain Always Associated with Somatosensory Cortex Activity and Reorganization? The Journal of Neuroscience 32: 14874–14884.
17. Gustin SM, Peck CC, Macey PM, Murray GM, Henderson LA (2013) Unraveling the Effects of Plasticity and Pain on Personality. The Journal of Pain 14: 1642–1652.
18. Henderson LA, Peck CC, Petersen ET, Rae CD, Youssouf AM, et al. (2013) Chronic Pain: Lost Inhibition? The Journal of Neuroscience 33: 7574–7582.
19. Cloninger R (1994) The temperament and character inventory (TCI): A guide to its development and use. St. Louis, MO: Washington University Center for Psychobiology of Personality.
21. Petersen ET, Lim T, Golay X (2006) Model-free arterial spin labeling quantification approach for perfusion MRI. Magn Reson Med 55: 219–232.

22. Friston KJ, Holmes AP, Poline JB, Grady PJ, Williams SC, et al. (1995) Analysis of fMRI time-series revisited. Neuroimage 2: 45–58.

23. Zermatten A, Van der Linden M, d’Acremont M, Jermann F, Bechara A (2005) Impulsivity and decision making. J Nerv Ment Dis 193: 647–650.

24. Vogt BA, Gabriel M (1993) Anterior cingulate cortex and the medial pain system. Neurobiology of cingulate cortex and limbic thalamus; a comprehensive handbook. Boston: Birkhauser.

25. Dietrich RB, Bradley WG, Zaragoza EJt, Otto RJ, Taira RK, et al. (1988) MR evaluation of early myelination patterns in normal and developmentally delayed infants. AJR Am J Roentgenol 150: 889–896.

26. Ono J, Kodaka R, Imai K, Ibukiya Y, Tanaka J, et al. (1993) Evaluation of myelination by means of the T2 value on magnetic resonance imaging. Brain Dev 15: 63–69.

27. Danielsen ER, Ross B (1999) Magnetic Resonance Spectroscopy Diagnosis of Neurological Diseases. New York, NY, USA: Marcel Dekker.

28. Urenjak J, Williams SR, Gadian DG, Noble M (1992) Specific expression of N-acetylaspartate in neurons, oligodendrocyte-type-2 astrocyte progenitors, and immature oligodendrocytes in vitro. J Neurochem 59: 33–61.

29. Clarke CE, Lowry M (2001) Systematic review of proton magnetic resonance spectroscopy of the striatum in parkinsonian syndromes. Eur J Neurol 8: 573–577.

30. Jung RE, Yeo RA, Chiulli SJ, Shibbitt WL, Jr, Brooks WM (2000) Myths of neuropsychology: intelligence, neurometabolism, and cognitive ability. Clin Neuropsychol 14: 535–545.

31. Brand A, Richter-Landsberg C, Leibfritz D (1993) Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci 15: 289–296.

32. Malmgren-Olsson E-B, Bergdahl J (2006) Temperament and Character Personality Dimensions in Patients With Nonspecific Musculoskeletal Disorders. The Clinical Journal of Pain 22: 625–631 610.1097/AJP.00000210907.0000210903.

33. Cloninger CR, Zohar AH, Hirschmann S, Dahan D (2012) The psychological costs and benefits of being highly persistent: Personality profiles distinguish mood disorders from anxiety disorders. Journal of Affective Disorders 136: 756–766.

34. Gusnard DA, Ollinger JM, Shulman GL, Cloninger CR, Price JL, et al. (2003) Persistence and brain circuitry. Proceedings of the National Academy of Sciences 100: 3479–3484.

35. Macey PM, Henderson LA, Macey KE, Alger JR, Frysinger RC, et al. (2002) Brain morphology associated with obstructive sleep apnea. Am J Respir Crit Care Med 166: 1382–1387.

36. Musen G, Lyssou IK, Sparks CR, Weiniger K, Hwang J, et al. (2006) Effects of type 1 diabetes on gray matter density as measured by voxel-based morphometry. Diabetes 55: 326–333.

37. Godlimy SE, Filipponi N, Donaud G, Carr AJ, Tracey I (2010) Thalamic atrophy associated with painful osteoarthritis of the hip is reversible after arthroplasty: a longitudinal voxel-based morphometric study. Arthritis Rheum 62: 2900–2940.

38. Taki Y, Kinomura S, Sato K, Inoue K, Goto R, et al. (2008) Relationship between body mass index and gray matter volume in 1,428 healthy individuals. Obesity (Silver Spring) 16: 119–124.